Evidence map›Paper›PMID 34196970›Full record

ArticleInternational journal of cancer2021

Circulating tryptophan metabolites and risk of colon cancer: Results from case-control and prospective cohort studies.

Nikos Papadimitriou, Marc J Gunter, Neil Murphy, Audrey Gicquiau, David Achaintre, Stefanie Brezina, Tanja Gumpenberger, Andreas Baierl, Jennifer Ose, Anne J M R Geijsen and 20 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Cancer pathogenesis and therapy · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 15 institutions in 10 countries.

Nikos PapadimitriouInternational Agency for Research on Cancer, Lyon, France.
Marc J GunterInternational Agency for Research on Cancer, Lyon, France.
Neil MurphyInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-3347-8249
Audrey GicquiauInternational Agency for Research on Cancer, Lyon, France.
David AchaintreInternational Agency for Research on Cancer, Lyon, France.
Stefanie BrezinaInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Tanja GumpenbergerInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Andreas BaierlDepartment of Statistics and Operations Research, University of Vienna, Vienna, Austria.
Jennifer OseHuntsman Cancer Institute, Salt Lake City, Utah, USA.ORCID 0000-0002-2030-9676
Anne J M R GeijsenDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
Eline H van RoekelDepartment of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Andrea GsurInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9795-1528
Biljana GigicDivision of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nina HabermannDivision of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cornelia M UlrichHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Ellen KampmanDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
Matty P WeijenbergDepartment of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Per Magne UelandBEVITAL, Bergen, Norway.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Verena KatzkeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Vittorio KroghEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.ORCID 0000-0003-0122-8624
Bas Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Eva ArdanazNavarra Public Health Institute, Pamplona, Spain.
Ruth C TravisCancer Epidemiology Unit, Department of Population Health, University of Oxford, Oxford, UK.
Matthias B SchulzeGerman Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Maria-José SánchezCIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Sandra M Colorado-YoharCIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Elisabete WeiderpassInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-2237-0128
Augustin ScalbertInternational Agency for Research on Cancer, Lyon, France.
Pekka Keski-RahkonenInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-9437-3040
Centre international de recherche sur le cancer · FRGerman Cancer Research Center · DEComprehensive Cancer Center Vienna · ATMaastricht University · NLUniversity of Utah · USWageningen University & Research · NLBevital (Norway) · NOFondazione IRCCS Istituto Nazionale dei Tumori · ITInstituto de Salud Pública de Navarra · ESNational Institute for Public Health and the Environment · NLUniversidad de Antioquia · COUniversidad de Granada · ESUniversity of Oxford · GBUniversity of Potsdam · DEUniversity of Vienna · AT

Funding

Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Mechanisms of Papillomavirus NeutralizationR01CA118790 · NCI · JOHNS HOPKINS UNIVERSITY · PI RODEN, RICHARD BRUCE · 2007 to 2018
$2.9M
Cancer Research UK 29017NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS U01 CA206110World Health Organization 001
6 · The paper itself

Abstract

Dysregulation of tryptophan metabolism has been linked to colorectal tumorigenesis; however, epidemiological studies investigating tryptophan metabolites in relation to colorectal cancer risk are limited. We studied associations of plasma tryptophan, serotonin and kynurenine with colon cancer risk in two studies with cancer patients and controls, and in one prospective cohort: ColoCare Study (110 patients/153 controls), the Colorectal Cancer Study of Austria (CORSA; 46 patients/390 controls) and the European Prospective Investigation into Cancer and Nutrition (EPIC; 456 matched case-control pairs). Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for colon cancer risk. Tryptophan was inversely associated with colon cancer risk in ColoCare (OR per 1-SD = 0.44; 95% CI, 0.31-0.64) and EPIC (OR per 1-SD = 0.86; 95% CI, 0.74-0.99). Comparing detectable vs nondetectable levels, serotonin was positively associated with colon cancer in CORSA (OR = 6.39; 95% CI, 3.61-11.3) and EPIC (OR = 2.03; 95% CI, 1.20-3.40). Kynurenine was inversely associated with colon cancer in ColoCare (OR per 1-SD = 0.74; 95% CI, 0.55-0.98), positively associated in CORSA (OR per 1-SD = 1.79; 95% CI, 1.27-2.52), while no association was observed in EPIC. The kynurenine-to-tryptophan ratio was positively associated with colon cancer in ColoCare (OR per 1-SD = 1.38; 95% CI, 1.03-1.84) and CORSA (OR per 1-SD = 1.44; 95% CI, 1.06-1.96), but not in EPIC. These results suggest that higher plasma tryptophan may be associated with lower colon cancer risk, while increased serotonin may be associated with a higher risk of colon cancer. The kynurenine-to-tryptophan ratio may also reflect altered tryptophan catabolism during colon cancer development.

Indexed as

AdultAgedAged, 80 and overCase-Control StudiesColonic NeoplasmsFemaleHumansKynurenineLogistic ModelsMaleMiddle AgedProspective StudiesRisk FactorsSerotoninTryptophanKynurenineSerotoninTryptophancolon cancerkynurenineplasmaserotonintryptophan

Identifiers

PMID34196970
PMCPMC8429124
OpenAlexW3176383647

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.